De novo gastric adenocarcinoma 1 year after sleeve gastrectomy in a transplant patient

M. Masrur*, E. Elli, L.F. Gonzalez-Ciccarelli, P.C. Giulianotti

Minimally Invasive & Robotic Surgery, University of Illinois Hospital and Health Science System, Chicago, IL, United States

1. Introduction

The relationship between a high body mass index (BMI) and malignancies has been well established as obesity is associated with an increased susceptibility to gastric and esophageal adenocarcinoma [1–3]. It is not clear whether bariatric surgery may represent a risk factor for the development of esophageal and/or gastric cancer [4]. Sleeve gastrectomy (SG) has become one of the most popular surgical procedures for weight loss in obese patients due to its safety, technical simplicity, resolution of co-morbidities and exceptional weight loss outcomes [5]. In the past 20 years there have been few studies reporting malignancies after bariatric surgery [3,4], with only 2 reported cases of esophago-gastric adenocarcinoma after sleeve gastrectomy [6,7].

The aim of this study is to report a case of de novo gastric adenocarcinoma occurring in a transplant patient 1 year after sleeve gastrectomy.

2. Case report

A 44-year-old woman with a BMI of 38 kg/m² and a past medical history of hypertension, type 1 diabetes mellitus, hyperlipidemia, bipolar disorder, sleep apnea, vaginal dysplasia, grade III vulvar intraepithelial neoplasia, anal condilomatosis and of heavy tobacco use; past surgical history of a pancreas transplant performed 4 years prior underwent laparoscopic sleeve gastrectomy (LSG). As part of the work up, a swallow contrast study showed grade 1 esophagitis. The patient underwent LSG and an incidental hiatal hernia was repaired without complications. Specimen was negative for histopathology changes and negative for Helicobacter pylori (pathology report: fundic type gastric mucosa and muscularis propria with negative for significant histopathologic changes).

Patient presented with an uneventful follow-up at 1, 3, 6, and 8 months. At the 8 month follow-up %EBWL was 52%, also presented with mild dysphagia to solids; an esophagogastroduodenoscopy (EGD) was performed that reported inflammation of the gastric...
esophageal mucosa with no strictures. The patient was discharged with proton pump inhibitor medication.

The patient returned to the hospital 3 weeks after with worsening symptomatology, extreme dysphagia to solids and liquid intolerance. A second EGD and fluoroscopy study were performed that showed a tight stricture, 10 cm from the gastroesophageal junction (Fig. 1). Endoscopic dilation of the area and random biopsies were performed. The pathology examination showed moderately differentiated grade 2/3 adenocarcinoma and positive immunostain to HER2/NEU. A CT scan was performed for stratification that showed a thickened gastric sleeve wall with no other metastatic nodules.

The patient underwent a minimally invasive approach, a 12 mm trocar for the robotic camera was placed left to the umbilicus with mid clavicle line, 8 mm robotic trocar for the 1st arm was placed subcostal following the left anterior axillary line, the 2nd and 3rd arm trocars was placed in the subcostal area following the right mid clavicular line and anterior axillary line, respectively, for the assistant port the trocar was placed 5 cm medially of the 2nd arm, the robot cart was docked from the head of the patient (Fig. 2). During the operation a rigid stomach was found with dysplastic changes in the gastric esophageal junction and thickening of the distal esophagus (Fig. 3). The tumor was invading transmurally into the perigastric adipose tissue and focally into the visceral peritoneum, pancreatic stromal tissue, transverse colon and distal esophagus. Robot-assisted total gastrectomy with a Roux-en-Y intracorporeal esophagojejunostomy, omentectomy, distal esophagectomy, distal splenopancrectectomy, tangential colon resection with a feeding jejunostomy were all performed (Figs. 4 A–D and 5 A–D).

The histologic examination revealed poorly differentiated and diffused type grade 3 gastric adenocarcinoma (pT4b, pN3a). The resection margins were tumor free, while there were metastasis to 2/2 lesser curvature lymph nodes, 2/2 perigastric lymph nodes, 1/1 splenic lymph nodes and 4/4 esophageal pedicle lymph nodes.

The operation was completed within 360 min, with an approximate blood loss of 200 ml. The patient was transferred to the surgical intensive care unit (SICU) for monitoring. The patient presented with a postoperative bibasal pleural effusion while in the SICU requiring chest tube drainage, with no further complications. The patient was tolerating diet and was discharged on postoperative day 14th. Patient is currently doing well at 8 month follow-up, with no sign of recurrences. Patient completed chemotherapy using Herceptin.

3. Discussion

Gastroesophageal cancer following a bariatric procedure has been previously reported in the literature [3–6]. The diagnosis of gastroesophageal cancer following bariatric surgery is usually late since these patients present with common upper gastrointestinal symptoms related to the procedure such as oral intolerance, nausea and vomiting.
Fig. 4. Intraoperative view of transection at 1st portion of duodenum (A), transverse colon invasion (B), transection of distal pancreas (C) and M-block dissection of distal pancreas (D).

Fig. 5. Intraoperative view of mediastinal dissection of distal esophagus (A), transection of distal esophagus (B), jejuno-jejunostomy (C) and esophago-jejunostomy with circular stapler (D).
To our knowledge this is the third reported case of de novo gastric cancer after LSG; nonetheless, it appears to be the bariatric procedure least related to cancer when compared with other bariatric procedures. Previous reports showed a case of adenocarcinoma of the lower esophageal sphincter (T2N1Mx) diagnosed 4 month after SG in a patient that did not undergo a preoperative EGD evaluation [5] and a second case of signet-ring cell adenocarcinoma of the body, antrum and pylorus of the stomach with lymph nodes metastasis (T4N1Mx) diagnosed 4 years after SG [6].

In our case, the cancer was aggressive and locally invasive, involving continuous organs and lymph nodes. The patient had several known risk factors for cancer. She was morbidly obese, a heavy cigarette smoker, immunosuppressed post pancreatic transplant and presented other neoplasm (grade III vulvar intraepithelial neoplasia, anal condilomatosis). In consideration of the patient’s transplant history and immune suppression therapy, laparoscopic sleeve gastrectomy was the procedure chosen for the metabolic and restrictive changes, avoiding the malabsorption component of alternative procedures that can jeopardize the outcome of the transplant by adjusting the immunosuppressive medication [8].

The increase in minimally invasive surgical skills provided by the robotic system allows for complex multiorgan resections while preserving the benefits of the minimally invasive surgical approach.

Despite the reported occurrences of upper gastrointestinal cancer following bariatric surgery, the incidence continues to be very low to suggest implementing a specific screening prior to SG. Although previous reports suggest performing EGD’s routinely [9], there is not enough data to support the need for further screening. In our practice EGD’s are not performed routinely, unless patients present with suspicious symptoms. Patients do undergo routinely Upper GI swallow test pre-operatively with the aim of detecting asymptomatic hiatal hernias.

4. Conclusion

No direct relation has been established between sleeve gastrectomy and the development of gastric cancer. We believe it is important to report this occurrence to better understand the nature or relation of bariatric surgery and upper gastrointestinal cancer. Further studies are needed in order to draw definitive conclusions regarding screening and the role of the preoperative EGD.

Conflicts of interest

Dr. Giulianotti has a consultant agreement with Covidien. The Department of Surgery at the University of Illinois has a proctoring agreement with Intuitive Surgical. Dr. Giulianotti as faculty included in this agreement provides proctoring services but is not remunerated. Financial benefits from this proctoring agreement are directly paid to the University of Illinois, Department of Surgery. Intuitive Surgical has provided a grant to the University of Illinois, Division of General, Minimally Invasive and Robotic Surgery. Dr. Giulianotti is the Chief of the Division and has no personal financial benefits resulting from this grant. None of the other authors have potential conflicts of interest to declare.

Funding

No sponsor involvement.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images.

Author contribution

Mario Masrur: contributed on study concept. Mario Masrur and Luis Fernando Gonzalez Ciccarelli contributed on data collection, analysis and interpretation and wrote the manuscript. Fernando Eili and Pier Giulianotti: acting surgeons, data analysis and interpretation, reviewed and commented manuscript.

Guarantor

Pier C. Giulianotti.

References

[1] A.G. Renehan, M. Tyson, M. Egger, R.F. Heller, M. Zwahlen, Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies, Lancet 371 (2008) 569–578.
[2] C.C. Abnet, N.D. Freedman, A.R. Hollenbeck, J.F. Fraumeni, M. Leitzmann, A. Schatzkin, A prospective study of BMI and risk of esophageal and gastric adenocarcinoma, Eur. J. Cancer. 44 (3) (2008) 465–471.
[3] G. Scocazzi, R. Trapani, M. Toppino, M. Morino, Esophagogastric cancer after bariatric surgery: systematic review of the literature, Surg. Obes. Relat. Dis. 9 (2013) 133–142.
[4] G. Orlando, V. Pilone, A. Vitiello, R. Gervasi, M. Lerose, G. Silecchia, et al., Gastric cancer following bariatric surgery: a review, Surg. Laparosc. Endosc. Percutan. Tech. 24 (5) (2014) 400–405.
[5] R. Rosenthal, International sleeve gastrectomy expert panel consensus statement: best practice guidelines based on experience of >12,000 cases, Surg. Obes. Relat. Dis. 8 (2012) 8–19.
[6] A.F. Scheepers, E. Schoon, S.W. Nienhuijs, Esophageal carcinoma after sleeve gastrectomy, Surg. Obes. Relat. Dis. 7 (2011) 11–12.
[7] L. Angrisani, A. Santonicola, P. Iovino, Gastric cancer: a de novo diagnosis after laparoscopic sleeve gastrectomy, Surg. Obes. Relat. Dis. 10 (2014) 186–187.
[8] F. Eili, M. Masrur, P.C. Giulianotti, Robotic sleeve gastrectomy after liver transplantation, Surg. Obes. Relat. Dis. 9 (2013) 20–22.
[9] P. Praveenraj, R. Gomes, S. Kumar, P. Senthilnathan, R. Parathaasaranth, S. Rajanpanian, et al., Diagnostic yield and clinical implications of preoperative upper gastrointestinal endoscopy in morbidly obese patient undergoing bariatric surgery, J. Laparoendosc. Adv. Surg. Tech. 25 (8) (2015) 465–469.